8.1 Primary Brain Tumors: Gliomas, Meningiomas & Acoustic Neuromas

The landscape of neuro-oncology has shifted significantly with the advent of molecular diagnostics. A primary brain tumor originates from the cells within or surrounding the brain, rather than spreading from another part of the body. Understanding the distinction between various primary tumors, their molecular characteristics, and their clinical presentations is paramount for the neuroscience nurse providing comprehensive care.

WHO 2021 Classification of CNS Tumors

The World Health Organization (WHO) 2021 Classification of Tumors of the Central Nervous System marked a paradigm shift by officially integrating molecular and genetic markers with traditional histologic features to define tumor types. This integration allows for more accurate prognostication and targeted treatment planning. Tumors are graded from CNS WHO grade 1 to 4, rather than using Roman numerals as in previous editions.

• Grade 1: Generally benign, slow-growing, circumscribed, and potentially curable with surgical resection alone (e.g., Pilocytic astrocytoma).
• Grade 2: Slow-growing but infiltrative, with a tendency to progress to higher grades over time (e.g., IDH-mutant astrocytoma, grade 2).
• Grade 3: Malignant, with histological evidence of malignancy such as nuclear atypia and increased mitotic activity (e.g., Anaplastic astrocytoma, though the "anaplastic" terminology is being phased out in favor of grade designations).
• Grade 4: Highly malignant, rapidly growing, with microvascular proliferation and/or necrosis (e.g., Glioblastoma, IDH-wildtype).

Key Molecular Markers in Gliomas

Understanding molecular markers is no longer optional in neuro-oncology; it is central to diagnosis and management.

IDH1/2 Mutations

Isocitrate dehydrogenase (IDH) 1 and 2 mutations are defining markers for several glioma subtypes. The presence of an IDH mutation is generally a favorable prognostic indicator compared to IDH-wildtype tumors. For example, an adult-type diffuse glioma with an IDH mutation is classified as an Astrocytoma or Oligodendroglioma (if accompanied by 1p/19q codeletion), whereas an IDH-wildtype diffuse astrocytic glioma is now strictly classified as a Glioblastoma, regardless of the histologic grade.

1p/19q Codeletion

The complete deletion of both the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q) is the defining molecular signature of an Oligodendroglioma. Tumors that are both IDH-mutant and 1p/19q codeleted are remarkably sensitive to chemotherapy and radiation, offering a significantly better overall survival.

MGMT Promoter Methylation

O-6-methylguanine-DNA methyltransferase (MGMT) is a DNA repair enzyme that can undo the DNA damage caused by alkylating chemotherapeutic agents like temozolomide (TMZ). When the MGMT promoter is methylated (silenced), the cell cannot produce this repair enzyme, rendering the tumor much more susceptible to TMZ. Thus, MGMT promoter methylation in glioblastoma is a strong predictive biomarker for treatment response.

Major Primary Tumor Types

Gliomas

Gliomas are the most common primary intra-axial brain tumors, arising from glial cells. They range from low-grade (slow-growing) to high-grade (aggressive) variants.

• Glioblastoma (GBM): Now strictly defined as an adult-type, IDH-wildtype, CNS WHO grade 4 diffuse astrocytic glioma. It is the most common and aggressive malignant primary brain tumor. Patients often present with rapidly progressive neurologic deficits, increased intracranial pressure (ICP), and seizures. MRI classically shows a "butterfly" lesion crossing the corpus callosum with ring enhancement and central necrosis.
• Oligodendrogliomas: These are typically slow-growing, IDH-mutant, and 1p/19q-codeleted tumors. They have a strong predilection for the frontal lobes and frequently present with seizures. Histologically, they are famous for the "fried egg" appearance of cells and a "chicken-wire" capillary network.

Meningiomas

Meningiomas are the most common primary brain tumor overall, though they are usually benign and extra-axial (outside the brain parenchyma). They arise from the arachnoid cap cells of the meninges. Because they are slow-growing, they often reach a substantial size before causing symptoms due to mass effect and compression of adjacent structures rather than direct invasion. Common locations include the parasagittal region, falx, convexity, and skull base. Treatment primarily involves surgical resection, and the Simpson grading system is used to evaluate the extent of resection, which correlates with recurrence risk.

Acoustic Neuromas (Vestibular Schwannomas)

Acoustic neuromas are benign, slow-growing tumors arising from the Schwann cells of the vestibular portion of the eighth cranial nerve (CN VIII). They typically originate in the internal auditory canal and can grow into the cerebellopontine angle.

Clinical Presentation

The hallmark presentation of an acoustic neuroma involves progressive, unilateral sensorineural hearing loss, tinnitus, and disequilibrium or mild vertigo. As the tumor expands in the cerebellopontine angle, it can compress adjacent structures, notably the facial nerve (CN VII), leading to facial weakness, twitching, or paralysis. Larger tumors may compress the trigeminal nerve (CN V), causing facial numbness, or eventually compress the brainstem and cerebellum, leading to ataxia and hydrocephalus. Bilateral acoustic neuromas are the hallmark of Neurofibromatosis Type 2 (NF2).

The Role of the Neuroscience Nurse

Caring for patients with primary brain tumors requires a deep understanding of neuroanatomy to anticipate deficits based on tumor location. For instance, a patient with a frontal lobe glioma will require vigilant assessment for executive dysfunction, personality changes, and expressive aphasia. The nurse must also monitor for signs of elevated ICP, manage seizure precautions, and provide extensive psychosocial support to patients and families navigating a devastating diagnosis. Educating the patient on the significance of their specific molecular pathology empowers them to better understand their treatment trajectory.